Patents by Inventor Mark Sliwkowski

Mark Sliwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20200048362
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: February 19, 2019
    Publication date: February 13, 2020
    Inventors: Walter Blattler, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY MAYTANSINOID CONJUGATES
    Publication number: 20170106097
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 1, 2016
    Publication date: April 20, 2017
    Inventors: Walter BLATTLER, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20150110816
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 23, 2015
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Ralph SCHWALL
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20140212411
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., IMMUNOGEN, INC.
    Inventors: Walter BLATTLER, Ralph SCHWALL, Mark SLIWKOWSKI, Sharon ERICKSON, Ravi V.J. CHARI
  • ErbB3 ANTIBODIES
    Publication number: 20130209495
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: March 22, 2013
    Publication date: August 15, 2013
    Applicant: GENENTECH, INC.
    Inventors: Robert Akita, Mark Sliwkowski
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20130108620
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 2, 2013
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Gail Colbern Schwall
  • ErbB2 and ErbB3 chimeric heteromultimer receptors
    Patent number: 8226935
    Abstract: Chimeric heteromultimer adhesins that bind the ligand of natural heromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of the ErbB2 and ErbB3 and ErbB2 and ErbB4. The chimeric ErB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: July 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • ErbB3 ANTIBODIES
    Publication number: 20120014969
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Robert Akita, Mark Sliwkowski
  • ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES
    Publication number: 20110293614
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Application
    Filed: November 24, 2009
    Publication date: December 1, 2011
    Inventors: Klaus Elenius, Maija Hollmen, Mark Sliwkowski
  • HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES
    Publication number: 20110129464
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Application
    Filed: December 16, 2010
    Publication date: June 2, 2011
    Inventors: CAMELLIA W. ADAMS, Leonard G. Presta, Mark Sliwkowski
  • Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
    Patent number: 7862817
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: January 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20100303834
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: June 30, 2010
    Publication date: December 2, 2010
    Inventors: BELINDA CAIRNS, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang, Mark Sliwkowski
  • METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20100136033
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 3, 2010
    Applicant: IMMUNOGEN, INC.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Chimeric Heteromultimer Adhesins
    Publication number: 20100135957
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 3, 2010
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • ErbB2 and ErbB3 chimeric heteromultimer adhesins
    Patent number: 7659368
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
    Patent number: 7618631
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: November 17, 2009
    Assignee: Genentech, Inc.
    Inventor: Mark Sliwkowski
  • ?-heregulin
    Patent number: 7585673
    Abstract: A novel member of the heregulin superfamily has been identified which is designated “?-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. ?-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of ?-HRG nucleic acid for the recombinant production of ?-HRG). ?-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: September 8, 2009
    Assignee: Genentech, Inc.
    Inventors: Gabriele Maria Schaefer, Mark Sliwkowski
  • Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
    Patent number: 7575748
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: August 18, 2009
    Assignee: Genentech, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
    Patent number: 7537931
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: May 26, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • Treatment with anti-ErbB2 antibody combinations
    Patent number: 7501122
    Abstract: The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: March 10, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski